Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 08:18 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Second Oncology Candidate (VTX-0P4) in a Prostate Stem Cell Antigen (PSCA) Related Tumor Study in Combination with a Checkpoint Inhibitor (CPI) / anti-mPD-1

Voltron Therapeutics announced that data from Study VTX-IO-004 demonstrated clear proof of concept for the self-assembling therapeutic, VTX-0P4.
July 20, 2021 09:00 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. Poznansky has Guest Essay Published in the New York Times

NEW YORK, July 20, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that a the Company’s Scientific Co-Founder, Dr. Mark C. Poznansky’s guest essay titled “The Vaccines We Have...
April 13, 2021 08:00 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc. Announces COVID-19 and Pandemic Preparedness Presentation to Congressional Offices and Agencies, Including HHS, NIH, FDA, and DoD

NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on...
March 24, 2021 08:00 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV)...
February 09, 2021 08:00 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV)...
January 28, 2021 09:15 ET | Source: Voltron Therapeutics, Inc.

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors. As a...
November 16, 2020 11:30 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc. to Participate in the 2020 Fall Defense TechConnect Virtual Innovation Summit

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense...
September 16, 2020 09:40 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc. Executes Manufacturing Agreement with Global Pharmaceutical Contract Development and Manufacturing Organization

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract...
September 15, 2020 08:30 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc. Announces Completion of First Small Animal Safety and Immunogenicity Study Assessing the Effect of Novel COVID-19 Vaccine, HaloVax™

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today the successful completion of its previously announced first small animal safety and immunogenicity study...
July 09, 2020 09:25 ET | Source: Voltron Therapeutics, Inc.

Voltron Therapeutics Retains Buenaventura Advisors, LLC to Explore Strategic Alternatives for its HaloVax™ Subsidiary

NEW YORK , July 09, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. (the Company) announced today it has retained Buenaventura Advisors, LLC to explore strategic alternatives for HaloVax, a...